PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Flunarizine dihydrochloride - Migraine (prevention)
PAD Profile : Flunarizine dihydrochloride - Migraine (prevention) Important
Keywords :
migraine prevention, migraine prophylaxis
Important Information :
Restricted to use in patients who are intolerant or refractory to other treatment options
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Pizotifen malate
- Erenumab
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Candesartan cilexetil
- Clonidine hydrochloride
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
05 November 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN supports the use of Flunarizine as a treatment option for the prophylactic treatment of migraine in the small number of patients who are refractory to other treatment options or who are unable to tolerate other available treatment options. It will be considered as RED on the traffic light system.
Associated BNF Codes
04. Central Nervous System
04.07.04. Antimigraine drugs